We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity. We are creating new approaches to treat mental and behavioral disorders, and to enhance cognitive function in healthy people.
(BUSINESS WIRE) Adare Pharmaceuticals and NLS Pharmaceutics Collaborate to Develop Mazindol Controlled Release (CR) for the Treatment of ADHD and Narcolepsy
Business Worldwide Magazine Spring 2019 issue: Alex Zwyer - Co-founder and CEO of NLS Pharmaceutics Ltd. (NLS) - explains the discovery and benefits of his organisation’s revolutionary medication.
ADHD and its medications: An Illustrated History Over Time, by Eric Konofal MD, PhD. It is the first book totally devoted to the history of ADHD, encompassing the literary, philosophical, medical, neuropsychological and therapeutical aspects of attention, hyperactivity and ADHD, with more than 400 illustrations and 500 bibliographic references
A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)
Recent Comments